Prostate Cancer Metastatic clinical trials

Explore recruiting prostate cancer metastatic clinical trials.

Recruiting prostate cancer metastatic studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Prostate Cancer Metastatic trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

(21140 ARANOTE) A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide in addition to androgen deprivation therapy (ADT) versus placebo plus ADT in men with metastatic hormone-sensitive prostate cancer (mHSPC).

Spain, Latvia, Lithuania

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects with Metastatic Hormonesensitive Prostate Cancer (mHSPC)

Czechia, Spain, Romania

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Multi-arm, Open-label Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD5305 in Combination with New Hormonal Agents in Patients with Metastatic Prostate Cancer (PETRANHA)

Italy

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 2 Open-label Extension Study for Subjects with Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Germany, Spain, Romania, Belgium, Italy, Sweden +9 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1b Study of JNJ-78278343, Targeting Human Kallikrein 2 (KLK2), in Combination with Other Agents for Metastatic Prostate Cancer

Spain

Human Pharmacology (Phase I)- Other EU CTIS Study details

Phase I study of 225Ac-PSMA I&T in prostate cancer

Netherlands

Human Pharmacology (Phase I)- Bioequivalence Study EU CTIS Study details

Prostate Cancer Metastatic trials by city

Prostate Cancer Metastatic in Toronto Prostate Cancer Metastatic in Vancouver Prostate Cancer Metastatic in Montreal Prostate Cancer Metastatic in Calgary Prostate Cancer Metastatic in Edmonton Prostate Cancer Metastatic in Ottawa Prostate Cancer Metastatic in Winnipeg Prostate Cancer Metastatic in Quebec City Prostate Cancer Metastatic in Hamilton Prostate Cancer Metastatic in Kitchener Prostate Cancer Metastatic in London Prostate Cancer Metastatic in Halifax Prostate Cancer Metastatic in New York Prostate Cancer Metastatic in Los Angeles Prostate Cancer Metastatic in Chicago Prostate Cancer Metastatic in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease